Jeff Isaacson

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso et al. · The Lancet · 2017 · 1.7K citations · Full text

Medicine, Gynecology, Oncology +12

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Elizabeth M. Swisher, Kevin Lin, Amit M. Oza et al. · The Lancet Oncology · 2016 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +12

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors

Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris et al. · Clinical Cancer Research · 2017 · 236 citations

Medicine, Oncology, Pharmacology +16

Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity

Elizabeth Poplin, Harpreet Wasan, Lindsey Rolfe et al. · Journal of Clinical Oncology · 2013 · 158 citations · Full text

Medicine, Oncology, Pharmacology +17

Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody

Steffen Ormanns, Volker Heinemann, Mitch Raponi et al. · European Journal of Cancer · 2014 · 36 citations

Medicine, Oncology, Pharmacokinetics +8